Enlivex Therapeutics Ltd. Ordinary Shares - ENLV STOCK NEWS

Enlivex Therapeutics has reported promising results from a Phase Ib trial of Allocetra^TM for severe sepsis. Comparing 10 treated patients to 37 matched controls revealed significant benefits: zero mortality in the treated group versus 27% in controls, a 58% reduction in ICU stay (4.7 vs. 11.1 days), and no increase in organ-failure among treated patients. The trial confirms Allocetra^TM as a safe and potentially effective treatment option for sepsis, a condition currently lacking effective therapies. Full data is available on medRxiv.org.

Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced a new patent from the China National Intellectual Property Administration for its immunotherapy product, Allocetra^TM. This patent strengthens the Company's intellectual property rights in China by covering methods, uses, and pharmaceutical compositions associated with Allocetra^TM, aimed at treating life-threatening conditions such as sepsis and COVID-19. Enlivex focuses on developing immunotherapies for unmet medical needs, particularly in organ dysfunction and cancer therapies.

Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced positive interim results from its Phase II clinical trial of Allocetra^TM in severe and critical COVID-19 patients. Out of eight treated patients, seven fully recovered and were discharged within an average of 4.7 days, while one patient improved from critical to moderate/severe. The treatment was well tolerated with no serious adverse events reported. The trial is part of a multi-center study aimed at evaluating Allocetra^TM alongside standard care for the target patient population.

Enlivex Therapeutics has announced a positive clinical outcome for a 70-year-old patient with erosive osteoarthritis treated with Allocetra™. After five weekly infusions, the patient showed significant improvement, including a 93% reduction in CRP levels and no need for re-hospitalization over 24 months. This case marks a notable achievement in treating a rare disease with no effective options. Allocetra™ is also undergoing clinical studies for other conditions, including COVID-19.

Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced the appointment of Dr. Brian Schwartz to its Board of Directors, effective November 15, 2020. Dr. Schwartz previously served as Chief Medical Officer at ArQule, leading its R&D until its $2.7 billion acquisition by Merck in February 2020. He expressed optimism about Enlivex’s Allocetra^TM program, which is in clinical trials for sepsis and COVID-19, indicating strong potential for significant impacts on high-mortality diseases. Shai Novik, Executive Chairman, welcomed Dr. Schwartz's extensive experience in product development, which is expected to enhance shareholder value.

Enlivex Therapeutics Ltd. (Nasdaq: ENLV) will present its clinical development schedule for Sepsis, COVID-19, and Solid Cancer during a fireside chat at H.C. Wainwright’s 6th Annual Israel Conference on November 12, 2020. The Phase IIb trial for sepsis patients is set for Q4 2020, expecting 160 patient enrollments with interim results anticipated in Q3 2021. The ongoing COVID-19 Phase II trial will provide interim results by year-end 2020. Enlivex is also pursuing collaborations for solid cancer therapies, focusing on unmet medical needs in immune system rebalancing.

Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced that the U.S. Patent and Trademark Office issued a notice of allowance for a new patent on Allocetra™, its immunotherapy product. This patent covers treatment methods for autoimmune and inflammatory diseases like gout and Crohn’s disease. Enlivex aims to utilize Allocetra™ for life-threatening conditions with no effective treatments, including sepsis and COVID-19. CEO Oren Hershkovitz expressed optimism about Allocetra™'s potential in immune rebalancing, highlighted by preclinical data supporting its applicability.

Enlivex Therapeutics Ltd. (Nasdaq: ENLV) has received authorization from the Israeli Ministry of Health to start a Phase IIb clinical trial for Allocetra™ in sepsis patients. This multi-center, placebo-controlled trial aims to enroll up to 160 patients, assessing safety, tolerability, and efficacy over 28 days. The company previously reported impressive Phase Ib results, showing zero mortality in Allocetra™-treated patients compared to 27% in controls. Allocetra™ has also been evaluated for COVID-19 treatment, with recent Phase Ib results indicating positive outcomes for five patients.

Enlivex Therapeutics Ltd. (Nasdaq: ENLV) has announced a Key Opinion Leader webinar on November 5, 2020, focusing on COVID-19 treatment options, featuring Dr. Carlos Cordon-Cardo from Mount Sinai hospital. The session will discuss findings from over 68,000 COVID-19 patients and the potential of Allocetra™ as a treatment for severe cases. Recent Phase Ib trial results show that all five patients treated with Allocetra™ recovered. A Phase II trial is underway to further evaluate Allocetra™ in combination with standard care for 24 patients. No severe adverse events were reported.